Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT01308931

The Effect of Birth Control Methods on Anti-Mullerian Hormone (AMH) Levels

The Effect of Tubal Ligation, Essure Placement, AND Levonorgestrel Intrauterine Device on Serum Anti-Mullerian Hormone Rates Over Time

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Valleywise Health · Academic / Other
Sex
Female
Age
25 Years – 40 Years
Healthy volunteers
Not accepted

Summary

Anti-mullerian hormone (AMH) has been shown to be a reliable marker of ovarian reserve. In prior studies, tubal ligation has been shown to have an adverse effect on ovarian reserve. One theory postulated for this effect is that the ovarian circulation is disrupted by the procedure, leading to altered hormone production. In this prospective cohort study, the investigators plan to analyze the rates of AMH decline by comparing the following contraceptive methods: tubal ligation, Essure placement, and levonorgestrel intrauterine devices (IUDs).

Detailed description

Anti-mullerian hormone (AMH) has been shown to be a reliable marker of ovarian reserve because levels demonstrate a consistent age-related decline and do not fluctuate throughout the menstrual cycle. In prior studies measuring markers other than AMH, tubal ligation has been shown to have an adverse effect on ovarian reserve. The primary aim of this study will be to compare the rates of anti-mullerian hormone (AMH) decline following tubal ligation, Essure placement, and levonorgestrel IUDs, and then identifying any and all differences that these specific contraceptive methods have on the changes of AMH rates over time. The secondary aim will focus on analyzing the various types of tubal ligation methods (i.e. coagulation, ligation, clips, bands, etc.) to see if different techniques result in any difference in the rate of AMH decline. The hypothesis is that tubal ligation will result in an accelerated rate of AMH decline as compared to other long-term or permanent contraceptive methods.

Conditions

Timeline

Start date
2013-01-01
Primary completion
2015-01-01
Completion
2015-01-01
First posted
2011-03-04
Last updated
2014-08-05

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01308931. Inclusion in this directory is not an endorsement.